FDA Approves Rivaroxaban Starter Pack

The U.S. Food and Drug Administration (FDA) has approved the use of the Xarelto (rivaroxaban) Starter Pack for patients at risk of another deep vein thrombosis (DVT) and/or pulmonary embolism (PE) after an initial occurrence. The FDA approved rivaroxaban in November 2012 as an anticoagulant used for the treatment of DVT and/or PE. The starter pack simplifies the dosing during the initial 30-day treatment period, when patients are most susceptible to another DVT or PE, by allowing treatment to continue between hospital discharges and follow-up visits. Read more about previous FDA decisions regarding rivaroxaban.

Clinical Topics: Anticoagulation Management, Vascular Medicine

Keywords: Anticoagulants, Morpholines, Pulmonary Embolism, Thiophenes, United States Food and Drug Administration, Venous Thrombosis


< Back to Listings